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Optogenetics is the use of genetically encoded light-activated proteins to manipulate
cells in a minimally invasive way using light. The most prominent example is
channelrhodopsin-2 (ChR2), which allows the activation of electrically excitable cells
via light-dependent depolarization. The combination of ChR2 with hyperpolarizing-light-
driven ion pumps such as the Cl− pump halorhodopsin (NpHR) enables multimodal
remote control of neuronal cells in culture, tissue, and living animals. Very soon, it became
obvious that this method offers a chance of gene therapy for many diseases affecting
vision. Here, we will give a brief introduction to retinal function and retinal diseases;
optogenetic vision restoration strategies will be highlighted. We will discuss the functional
and structural properties of rhodopsin-based optogenetic tools and analyze the potential
for the application of vision restoration.
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RETINAL STRUCTURE, ORGANIZATION, AND SIGNAL
PROCESSING
The mammalian retina is a layered structure that sits at the back of the eyeball. It consists of five
neuronal cell classes (Masland, 2001; Nguyen-Ba-Charvet and Chédotal, 2014) and one major glial
cell type, the so-called Müller cells (Reichenbach and Bringmann, 2013). The distal layer is called
the outer nuclear layer (ONL) and it contains the cell bodies of rod and cone photoreceptors. The
inner nuclear layer (INL) consists of excitatory bipolar cells, as well as inhibitory horizontal and
amacrine cells. The ganglion cell layer (GCL) consists of ganglion cells: their axons are bundled
to form the optic nerve and relay light information to higher brain areas. Retinal neurons are
connected in two plexiform layers, the inner and outer plexiform layers (OPL), where most of
signal processing by inhibitory neurons takes place (Gollisch and Meister, 2010; Figure 1). Of note
is the inverse layered orientation: photoreceptors face inwards. As a consequence, light passes
through the entire retinal tissue before it can be detected by photoreceptors, with the notable
exception of the fovea. In the OPL, horizontal cells mediate lateral inhibition to precise visual
signals. Amacrine cell interactions in the inner plexiform layer (IPL) add multiple modes of visual
processing, for example direction selectivity. In addition, downstream of the photoreceptors,
two major, morphologically distinct pathways diverge, the ON and the OFF pathways, which
are activated by increments or decrements of light, respectively. ON and OFF bipolar cells
project onto corresponding retinal ganglion cells. It is thought that each aspect of the visual
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FIGURE 1 | Retinal structure. The vertebrate retina is a layered structure. The retinal pigment epithelium (RPE) cells send their apical processes into the
photoreceptor outer segment (POS) layer. The photoreceptors are densely packed and the layer containing their nuclei is called outer nuclear layer (ONL). Axons
spread from there to the outer plexiform layer (OPL), where the synapses between photoreceptors, excitatory bipolar cells and inhibitory horizontal cells are formed.
Along with the amacrine cells, their cell bodies and nuclei are located in the inner nuclear layer (INL). Amacrine cells create inhibitory synapses onto bipolar cells’
axons. Bipolar cells either depolarize their respective ganglion cells upon light stimulus (ON channel) or after the light stimulus (OFF channel). Inside the inner plexiform
layer (IPL), this precisely processed signal is finally processed and output via the axons of ganglion cells, which send action potentials along the optic nerve to higher
brain areas. Mixed ON/OFF channels also exist. Müller glia cells support neuronal functions and mediate important signals, e.g., immune responses. They are
considered more plastic, and spread their processes all over the retinal structure from the RPE to the inner limiting membrane (ILM). The light travels from the pupil
through the vitreous, hitting first the processing neuronal network before reaching the actual photoreceptors, hence the notion of an “inverted eye” in vertebrates.
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scene is transmitted via different parallel channels that are
formed by different ganglion cell types. It has been shown that
there are at least 30 different channels in mice (Roska and
Werblin, 2001; Baden et al., 2016). In summary, the retina
is not only a light-receiving element of the brain, but a tiny
sophisticated biological computer that first converts photons into
electrical signals then processes them before the information is
sent to higher brain areas.
PHOTORECEPTOR FUNCTIONS AND
RETINAL DEGENERATION DISEASES
A common feature of retinal degenerative diseases is the
progressive loss of photoreceptors (Bramall et al., 2010). As in
many other species, humans have two types of photoreceptors for
image-forming vision, the highly sensitive rods important for low
light vision and the less sensitive cones for high acuity daytime
and color vision (Dowling, 1970). There are three cone subtypes,
whichmainly differ in the spectral tuning of their photopigments,
cone opsins, and thereby facilitate trichromatic vision (Wald,
1964). Cone opsins and rhodopsins in rod photoreceptors are
G-protein-coupled receptors (GPCRs) that convert light into
electrochemical signals via a G-protein cascade that finally leads
to a hyperpolarization of the photoreceptor cell (Figure 2).
This process is called phototransduction and it takes place in
specialized cellular compartments, the outer segments (OS) that
are surrounded by retinal pigment epithelium (RPE) cells (Koch
and Dell’Orco, 2015). Neuronal activity in general is mediated
via the depolarization of the membrane potential, whereas
hyperpolarization results in neuronal inhibition. Therefore, it is
of note that photoreceptors are active in the dark and release
the neurotransmitter glutamate to the synaptic cleft, whereas
light-induced hyperpolarization stops the glutamate secretion
to which the postsynaptic bipolar and horizontal cells respond
(Heidelberger et al., 2005).
Cone photoreceptors are not evenly distributed over the
entire retina. These cells are clustered in the macula, of which
the central area called the fovea comprises the spot of highest
visual acuity (Provis et al., 1998). The fovea consists only
of cone photoreceptors: these project onto sideward-oriented
downstream retinal cells. Rodents lack a macula and therefore,
are not well suited for modeling human cone diseases such
as age-related macular degeneration (AMD; Mehta, 2015).
Nevertheless, there are many adequate mouse models for rod
diseases such as retinitis pigmentosa (RP). In RP, rods are
affected by mutations leading to night blindness (Hartong et al.,
2006). Later on, these cells degenerate and the death zone
progresses from the periphery towards the retinal center, which
results in tunnel vision. In the late stages, cone photoreceptors
lose their OS, become light insensitive and to some degree,
also degenerate, causing overall blindness. RP phenotypes, their
onset and progression are highly variable among patients, also
depending on the type of genetic mutation (Jacobson et al.,
2010). To date, more than 90 mutations causing RP have
been identified and mapped1. Thus, blindness is a consequence
1https://sph.uth.edu/retnet/home.htm
of functional impairments and degenerated photoreceptor
cells.
THERAPEUTIC STRATEGIES
Therapeutic interventions in degenerative diseases are a race
against time: it is necessary to intervene before degeneration
occurs. To date, treatments that reverse vision loss are still
in pioneering phase. For example, one of the most promising
examples is the RPE-65 gene transfer that is targeted to RPE
cells in Leber congenital aumorosis (LCA; Testa et al., 2013;
Weleber et al., 2016). In gene therapy approaches, the transfer
of a corrected copy of a disease-causing gene is limited by the
disease phenotype (it must be slow and recessive) and by the
size of the gene. The gold standard for ocular gene transfer
uses adeno-associated viruses (AAV) that can carry about 4.7 kb
of single-stranded DNA (Grieger and Samulski, 2005). AAV
particles are relatively small (20 nm in diameter) and the
viral single-stranded DNA genome is encapsulated in capsids,
which classifies their serotype. To date, there are different
serotypes in use, which target different cell surface receptors.
Therefore, this tropism can be adjusted to transfect preferred
cell types (Grieger and Samulski, 2005; Ojala et al., 2015;
Salganik et al., 2015). Therapeutic interventions for dominant
mutations additionally need a cellular depletion of the mutated
endogenous copy. In addition, interventions to stop or delay
the disease progression by applying neuroprotective factors
(Trifunovi c´ et al., 2012; Froger et al., 2014; Léveillard et al.,
2014) as well as substituting degenerated photoreceptors using
cell transplantations (Jayakody et al., 2015) are also being tested
extensively.
In this review, we will focus on optogenetic interventions.
An optogene confers light sensitivity to any targeted neuron
and thereby functionally turns it into artificial photoreceptors
(Fenno et al., 2011). Hence, applying optogenetic tools to
the remaining retinal neurons after the degeneration or
dysfunction of intrinsic photoreceptors was the obvious step.
This approach is mutation-independent and it is suited for
patients that lack or have non-functional photoreceptors and
are therefore legally blind. Still, a substantial number of other
retinal cell types has to be intact for optogenetic targeting.
We will highlight approaches that have the potential to
be tested, and some that are already being evaluated for
clinical trials, namely those where the optogenes fit into
recombinant AAV vectors. In addition to the optogene, suitable
promoter elements that mediate sufficient optogene expression
into the recombinant AAV genome are necessary. These
promoters are either cell-type-specific or mediate ubiquitous
expression. The choice depends on the availability and strength
of suitable elements, and the anticipated strategy of the
targeted cell types. In a laboratory setting, researchers can
control transgene expression via genetic tricks such as the
Cre-LoxP system, which is not applicable in therapeutic
approaches. Although there is a substantial body of interesting
optogenetic work in transgenic mice (Vann and Xiong, 2016),
here we will mostly focus on strategies that rely on AAV
transfer.
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FIGURE 2 | The phototransduction cascade in vertebrate photoreceptors. (A) In the dark, 11-cis retinal is bound to rhodopsin, which is located inside the
membrane of the outer segment’s (OS) discs. The G-protein transducin (T) and phosphodiestherase (PDE) are inactive (upper panel). Cyclic guanosine
monophosphate (cGMP) triggers the opening of cation channels in the photoreceptor membrane, which mediate a Na+ influx (middle panel). This in turn depolarizes
the membrane potential of the inner segment (IS) and triggers the release of glutamate (Glu) from ribbon synapses (lower panel). (B) Upon light absorption, 11-cis
retinal is converted to all-trans retinal and dissociates from the rhodopsin. This activates the transducin, which in turn activates PDE, whose catalytic activity degrades
cGMP (upper panel). This effectively lowers the cGMP concentration, which leads to closure of cation channels (middle panel). Thus, the IS is hyperpolarized and the
Glu exocytosis is stopped (lower panel). Due to the G-protein involved in the transduction, a very high amplification of single photon responses is possible.
THE BIOPHYSICS OF OPTOGENETICS
Especially when applying optogenetic tools to therapeutic
interventions, it is of high importance to understand the
strengths and limitations of microbial opsins. Here we present
the biophysical properties of the most important optogenetic
tools applied in neurobiology, with a focus on ophthalmic
diseases. We describe the molecular properties, important for
determining the appropriate application for vision restoration.
Two classes of microbial rhodopsin-based tools are used: light-
gated ion channels, named channelrhodopsins (ChR; Nagel
et al., 2003) and light-driven ion pumps such as the Cl− pump
halorhodopsin (NpHR; Duschl et al., 1988; Bamberg et al.,
1993) or the H+ pump Arch (Chow et al., 2010). Light-gated
anion channels also exist, both engineered (Berndt et al., 2014;
Wietek et al., 2014) or discovered in algae (Govorunova et al.,
2015; Wietek et al., 2016). However, these hyperpolarizing anion
channels have not yet been applied to confer light sensitivity
to blind retinas. Major points are light sensitivity and single-
channel parameters such as conductance and the lifetime of
the channel. All rhodopsins consist of a seven-transmembrane
helix motif, whereby the chromophore retinal is bound via
a Schiff base to the peptide chain of helix 7 (Figure 3).
Rhodopsins undergo a photocycle after light absorption. The
photocycle kinetics control the channel or pump activity. In
the case of the visual rhodopsins, the enzymatic cascade that
yields the hyperpolarization of the cells determines the speed of
activation.
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FIGURE 3 | Channelrhodopsin-2 (ChR2) structure. (A) Structural analysis using 2D and 3D crystallography has revealed that ChR2 appears as a dimer.
The channel-forming helices are helices 1, 2, 3, and 7 and two extracellular loops (ECL) are highlighted (Müller et al., 2011, 2015; Kato et al., 2012). (B) Helix
movement after light excitation of helices 2 and 7 (part of the cation pathway) was observed, as well as movement of helix. Panel (A) was modified from Kato et al.
(2012) and (B) from Müller et al. (2015).
CHANNELRHODOPSIN-2
Channelrhodopsin-2 (ChR2) is present in the ‘‘eyespot’’ of
the unicellular alga Chlamydomonas reinhardtii and its natural
function is connected with phototaxis to help the organism
obtain optimal light conditions (Sineshchekov et al., 2002). ChR2
is a light-gated cation channel with a high permeability for
protons, 106 times larger than its permeability for monovalent
cations Na+ and K+ (Nagel et al., 2003). There is also a
minor permeability for Ca2+. At physiological pH, however,
the proton conductance can be ignored due to the low
[H+]. In addition, ChR2 is a leaky, outwardly directed
proton pump, whereby the leak actually represents the natural
channel function (Feldbauer et al., 2009). The single channel
parameters were determined by noise analysis as single channel
conductance γ ≈ 80 fS and open probability Po ≈ 0.5
at room temperature and physiological ion concentrations.
These properties allow the determination of the number of
active ChR2 copies per cell in optogenetic experiments in
which n ≈ Iph / γPo, where Iph represents the measured
photocurrent.
ChR2 maximally absorbs blue light at 470 nm. At this
wavelength, the penetration into the tissue is poor as
compared to the recently published red light absorbing
ChR Chrimson with a peak of action at 590 nm because
of the scattered light and light absorption in the tissue
(Klapoetke et al., 2014). In addition, light sensitivity
and frequency response are important in the retina for
visual restoration. Depending on the transduced cell type,
frequencies between 30 and 800 Hz are necessary for
optimal activation. This implies that a shorter lifetime of
the channel results in a better frequency response of the
neuronal cell. Because of smaller ion translocation, the light
sensitivity is drastically reduced in a fast ChR, whereas
an increased channel lifetime yields an increased light
sensitivity. A typical quantum efficiency of rhodopsin-like
actuators is around 0.5, so that manipulation attempts to
increase this value can only lead to small increases in light
sensitivity. Only a higher ChR expression in the membrane
can increase the sensitivity, because all the single-channel
conductances of different ChRs tested so far are almost invariant
(Figure 4).
A drawback of using microbial opsins is the dynamic
range of applied light intensity, which usually does not
exceed more than one order of magnitude with respect to
the absorbed photons. Compared to the intact visual system
which senses light over nine orders of magnitude, this means
relatively high light intensities have to be applied to elicit a
reasonable light response in the mammalian retina, especially
for the fast ChR2 derivates. In other words, low ambient
light must be amplified, whereas high light intensities have
to be reduced. To achieve this in a therapeutic context, a
goggle has to be developed that consists of a digital camera
and a photodiode array (Cepko, 2010). The device allows
the camera image to be transformed into a constant high
photon density representation to the transduced cells in the
retina. Due to high light sensitivity of the digital cameras
within such a device, light intensities of up to five orders
of magnitude could be registered by the transduced retinal
cells.
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FIGURE 4 | Schematic representation of the light sensitivity of ChR2 variants with different lifetimes. The arrows indicate the light activation of the putative
single channels. The longer the lifetime, the more charge Q will be transported per absorbed photon, I is the single channel current. Light saturation is reached at
much lower light levels for the long-lasting channels than for short-term channels, as demonstrated by the number of absorbed photons.
LIGHT-DRIVEN ION PUMPS
Halorhodopsin from Natronomonas pharaonis (NpHR) is a
light-driven inwardly-directed Cl− pump, which hyperpolarizes
the archaebacterial cell by up to −200 mV (Duschl et al.,
1988; Bamberg et al., 1993). The resulting electrochemical
gradient is used for ATP synthesis and for the activation of
secondary transporters in the cell membrane. NpHR undergoes
a photocycle, where the Cl− transport is tightly coupled to its
kinetics, i.e., one unit charge per successful photocycle.
NpHRwas the first light-driven ion pump applied in neuronal
cells (Han and Boyden, 2007; Zhang et al., 2007). It has
been shown in an electrophysiological study that, after the
sequential absorption of two photons, the photocycle of NpHR
is short-circuited (Figure 5). This implies that the rate-limiting
step of the photocycle lasts 1.5 ms, which corresponds to a
turnover of 700 ions per second. It has also been shown that
the proton pump Arch has similar properties (Chow et al.,
2010; Kleinlogel et al., 2011b). Compared to activated wildtype
ChR2 with a lifetime of 10 ms, which transports 10,000 unit
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FIGURE 5 | The photocycle of halorhodpsin (NpHR). Flash photolysis
experiments revealed a dark-adapted and a light-adapted ground state, with
identical absorption maxima at 570 nm (Chizhov and Engelhard, 2001).
charges per second under physiological conditions, the NpHR
performance is only 10 times less (Feldbauer et al., 2009).
Depending on the expression level, a short light pulse which
initiates a single turnover of the rhodopsins is sufficient for
the activation or inactivation of neuronal cells by ChRs or
the light-driven ion pumps (Kleinlogel et al., 2011b). These
properties make these fast cycling ion pumps valuable tools for
the hyperpolarization of residual cone cells as demonstrated in




Very recently, alternate optogenetic approaches using human
rhodopsin or rhodopsin-like GPCRs have been applied. By
this procedure these intrinsic photoreceptor molecules could
be functionally expressed in other retinal cell types in
photoreceptor-deficient mouse retinas. This approach certainly
has potential, because these light-sensitive proteins activate
endogenous signal transduction cascades after light flashes. This
amplification step results in light sensitivities, several orders
of magnitude higher than those of the microbial rhodopsins




After the pioneering optogenetic publication in 2005 (Boyden
et al., 2005), two different vision restoration strategies were
described. First, an approach to target as many retinal cell types
as possible, mostly ganglion and amacrine cells (Bi et al., 2006).
In this approach, ON and OFF pathways would be phased to
ON, and other retinal processing would be lost. It was assumed
that the brain is plastic enough to extract and process the visual
input. Second, a cell-type-specific approach was applied to target
ON bipolar cells, aiming to restore inner retinal signal processing
features (Lagali et al., 2008). We now know from electronic
prosthesis, transplantation experiments that patients are able to
recognize letters and primitive visual schemes upon non-cell type
specific electrical stimulation (Stingl et al., 2015; Luo and da
Cruz, 2016). This indicates that a random retinal cell-targeting
approach will likely restore image-forming vision. Nevertheless,
whenever retinal cell types that are more upstream, such as
the remaining cone photoreceptors, and bipolar and amacrine
cells, can be targeted, retinal processing features will also be
restored. This will likely improve the quality of restored vision,
but ultimate proof will only come when the first treated patients
are tested.
Cell-type-specific approaches rely on promoter elements that
drive transgene expression exclusively in the target cell type. For
AAV-mediated optogene expression, small promoter elements
that provide relatively strong expression are needed; sufficient
amounts of proteins are also needed to cover the cell’s surface
membrane. The biggest limitation for retinal gene transfer is the
lack of specific and strong promoter elements to target individual
cell types in the retina. However, controlling expression in
photoreceptors and ON bipolar cells is already very efficient
(Li et al., 2008; Dalkara et al., 2013; Cronin et al., 2014)
and it is only a matter of time before promoter elements for
other cells of interest are identified and used. To date, there
are many unspecific promoter elements such as the chicken
beta-actin (CAG; Miyazaki et al., 1989) or cytomegalovirus
(CMV) promoter (Du et al., 1996) that provide strong gene
expression in multiple cell types and fit to recombinant AAV
genomes.
TARGETING GANGLION CELLS
Ganglion cells are the retinal output cells and their axons relay
visual information to higher brain areas. Upon photoreceptor
degeneration, ganglion cells persist in blind retinas and only
modest remodeling is reported (Marc et al., 2003; Jones
et al., 2016). Due to their persistence during disease, ganglion
cells are ideal cellular targets for optogenetic restoration of
visual function (Figure 6). However, it is notable that there
are no specific promoter elements that are only active in
ON, OFF, or ON-OFF ganglion cells for AAV gene transfer.
Therefore, it is necessary to apply ubiquitous promoters,
which would phase the ON, OFF and ON-OFF ganglion cells
to ON channels when using a depolarizing optogene. This
means that upstream retinal processing would be lost. As
mentioned above, the plasticity of higher brain areas likely
compensates for some loss of quality in the retinal output
signals. Additionally, specific promoter elements targeting
ganglion cell subpopulations will probably be developed in the
future.
Ganglion cells are located in the ganglion cell layer (GCL),
adjacent to the vitreous body (Figure 6). In rodents, AAV
administration into the vitreous space leads to efficient infection
of ganglion cells, specifically in mouse models, whereas in
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FIGURE 6 | Targeting retinal ganglion cells. In photoreceptor diseases
(e.g., retinitis pigmentosa, RP), cones lose their light-sensitive outer segments
(OS) and their cell bodies merge with the INL, but ganglion cells persist in blind
retinas. Along with their susceptibility to viral gene transfer through the
vitreous, this makes ganglion cells an ideal cellular target for optogenetic
restoration of visual function.
primates the inner limiting membrane (ILM) resembles a barrier
for AAV particles. The infected cells mostly cluster around the
foveal rim (Vandenberghe et al., 2013). A pan-retinal transfection
of ganglion cells would require additional removal of the ILM,
or would need recombinant AAV capsids that can transcend
it (Dalkara et al., 2009). Therefore, this difference in AAV
gene transfer between mice and primates highlights another
obstacle that has to be overcomed during the translational
process.
Pioneering optogenetic vision restoration work was
performed in the Pan lab in 2006 (Bi et al., 2006). Bi et al.
(2006) successfully delivered ChR2 that was driven by a CAG
promoter and fused to green fluorescent protein (GFP) via AAVs
to inner retinal neurons, mostly ganglion cells, of blind rd1 mice.
Thereby, robust ON responses were restored and transmitted to
higher brain areas, as demonstrated by measured visual evoked
potentials (VEP) in the visual cortex. Stable ChR2 expression
and function in ganglion cells could be detected in 18-month-old
rd1 mice without detectable toxicity, suggesting that long-term
ChR2 expression in mouse ganglion cells is safe (Ivanova and
Pan, 2009). Applying more sensitive ChR2 derivates led to
improved light sensitivity in mouse ganglion cells (Pan et al.,
2014).
This approach was further successfully tested in ganglion
cells of blind Royal College of Surgeons (RCS) rats, resulting
in reactivated ganglion cell spike responses, VEPs, and
improvements in visually guided behavioral tests (Tomita et al.,
2010). It is of note that AAV-mediated delivery of ChR2 in
younger animals was more effective than in aged rats with
progressed retinal degeneration (Isago et al., 2012). Surprisingly,
the subretinal delivery of AAVs also resulted in ChR2 expression
in non-retinal organs such as the heart, lung, and intestine
(Sugano et al., 2011). These data suggest that AAV particles
can exit the eyeball, remain infectious, and cause unwanted
ChR2 expression in other organs. Instead of using the CAG
promoter, a neuron-specific promoter element would likely
omit expression in non-neuronal cell types. Still, the overall
immune response against the viral capsids and ChR2 protein
was extremely mild, suggesting that long-term ChR2 expression
was well tolerated in rats (Sugano et al., 2011). It was also
shown that a modified Volvox channelrhodopsin-1 (mVChR1)
expressed in ganglion cells conferred a broad-spectrum light
sensitivity to former blind rats, resulting in VEPs and visually
guided behavioral test improvements (Tomita et al., 2014).
The usage of more red-shifted depolarizing optogenetic tools
(Chuong et al., 2014; Klapoetke et al., 2014) is favorable because
the 470 nm light needed to activate ChR2 can be phototoxic,
as high intensities are needed. Furthermore, blue light also
triggers the pupillary light reflex that is triggered by melanopsin-
expressing ganglion cells. Thereby, the amount of light that
reaches the retina is even more reduced (Thyagarajan et al.,
2010).
Another important step towards the clinical application of
ChR2 for vision restoration therapies is a successful translation
of ChR2 delivery, and functional as well as safety tests in
nonhuman primates. To this end, ChR2 delivery to ganglion cells
has already been established in marmosets, demonstrating the
overall feasibility, although very few animals were tested (Ivanova
et al., 2010). High ChR2 expression from the CAG and CMV
promoter was detectable at peripheral regions, whereas the foveal
regions were harder to target. ChR2-mediated light responses
were assessed by electrophysiology, but sophisticated tests for
immunogenicity have not yet been developed.
In order to deal with immunogenicity of microbial opsins
in human patients, intrinsic opsins would be a way to
circumvent potential immune responses. Richard Masland’s
group has successfully tested melanopsin, the photopigment
that is normally used by retinal ganglion cells for non-image-
forming vision (Lin et al., 2008). When overexpressing it
ectopically in ganglion cells, which do not normally express
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melanopsin, these cells became light sensitive and former
blind rd1 mice responded to light stimuli in behavioral tests.
However, two important drawbacks, which might get solved by
melanopsin protein engineering, are the low temporal resolution
(high latency) and kinetics (prolonged activity in the range
of seconds). Melanopsin belongs to the group of GPCRs and
therefore, the signals are amplified within the signaling cascade,
suggesting that less light is needed for activation. Consequently,
the functional activation of melanopsin in non-intrinsically
photosensitive retinal ganglion cells implies the recruitment
of intrinsic G-protein cascades downstream of the receptor
protein: it is unknown which alterations to the default signal
cascade occur. Despite the fact that it functionally works, more
mechanistic insights are needed to rule out unwanted side
effects in regular signal pathways. Also, an engineered DNA-
encoded light-gated ionotropic glutamate receptor (LiGluR) has
been developed and further improved for resensitizing blind
retinas of mice and dogs (Caporale et al., 2011; Gaub et al.,
2014). However, LiGluR functionally depends on a chemically
engineered photoswitch that needs to be co-injected. Despite
its advantages, this dual components approach would be more
difficult to translate than standalone optogenetic proteins that
use intrinsic retinal as a chromophore.
When targeting retinal ganglion cells, optogene expression
is not limited to the eyeball; axons and their terminals are
also decorated with light-sensitive molecules. Hence, even
a mild immune response would not be constrained to the
eyeball, which would be removable by surgery; it would
also be present in higher brain areas. Therefore, a restricted
expression by localizing sequences to the soma and dendrites
of ganglion cells would be desirable. In addition, by localizing
a hyperpolarizing tool to the dendritic tips, and a depolarizing
optogene to the soma, it has been shown that antagonistic
center-surround receptive field interactions could be mimicked
(Greenberg et al., 2011; Wu et al., 2013). In this light, targeting
ChR2 to ganglion cell axonal initial segments where action
potentials originate can improve light sensitivity and alter
firing patterns (Grubb and Burrone, 2010; Zhang et al., 2015).
Hence, the addition of localization sequences to optogenetic
tools further refines and improves their use for turning
retinal ganglion cells into artificial photo-sensing cells in blind
retinas.
TARGETING INNER RETINAL CELLS
The rationale for targeting inner retinal neurons, such as
amacrine and bipolar cells is to preserve certain retinal
processing features. In addition, optogene expression might
be contained within the retina for safety reasons. We have
learned that the injection of AAV particles into the vitreous
to target ganglion cells also results in ChR2 expression in
some amacrine cells, whereas gene delivery to bipolar cells
was extremely inefficient. Nevertheless, the use of ubiquitous
promoter elements in combination with in vitreal injection of
AAV particles that by default efficiently transfect ganglion cells
is suboptimal for two main reasons: first, the optogene responses
in ganglion cells would mask or overwrite light responses from
FIGURE 7 | Targeting ON bipolar cells. Some retinal processing features,
such as feed forward and lateral inhibition, can be restored when ON bipolar
cells are optogenetically modified to respond to light. Intrinsic photoreceptor
function is absent but not required.
inner retinal neurons; second, the GCLs would act like a sponge
and take away substantial amounts of viral particles before
they reach inner retinal cells by diffusion. Applying cell-type-
specific promoter elements and engineering viral capsids that
don’t get caught by ganglion cell surface receptors would be a
solution.
Indeed, Botond Roska’s group has shown that a small
sequence from the mGLUR6 promoter region (Kim et al.,
2008) was specific enough to restrict ChR2 expression in
ON bipolar cells of normally blind rd1 mice (Lagali et al.,
2008, Figure 7). This specific reactivation of the ON pathway
in the absence of intrinsic photoreceptor input led to light
responses in ON ganglion cells that were transmitted to the
visual cortex, as measured by VEPs. These formerly blind
mice were also able to perform significantly better in visually
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guided behavioral tests compared to blind littermates. It is
of importance that some retinal processing features, such
as feed forward and lateral inhibition, were restored: this
demonstrates the overall feasibility of restoring retinal processing
by optogenetic intervention further upstream in the retinal
pathways. Nevertheless, this first cell-type-specific approach
was restricted to in vivo electroporation for gene delivery
(Matsuda and Cepko, 2007), a method not suited for optical
gene transfer in patients. At that time, the default AAV
capsids failed to get efficiently incorporated into bipolar cells
independent of the injection site. Since then, extensive screens
with mutated, and thereby modified, viral capsids have been
performed for optimized transfection of mouse ON bipolar
cells (Dalkara et al., 2013). The efficient ChR2 expression
upon in vitreal administration of AAV particles has been
achieved, and has even been further improved by using several
repeats of the mGLUR6 promoter element (Doroudchi et al.,
2011; Cronin et al., 2014; Macé et al., 2015). Also, improved
ChR2 variants (Kleinlogel et al., 2011a) have been applied
to ON bipolar cells via AAV gene transfer (Cronin et al.,
2014).
To improve light sensitivity and reduce the potential
immunogenicity of microbial opsins, intrinsic and engineered
opsins have been applied to ON bipolar cells, similar to the
techniques for ganglion cells. For example, a fusion protein
from the intracellular domain of mGluR6 and melanopsin,
called Opto-mGluR6 was about 4 log units more sensitive than
wildtype ChR2 (van Wyk et al., 2015), likely because of the
incorporation of a pre-existing G-protein cascade for signal
amplification. The kinetics of Opto-mGluR6-mediated light
responses in ON bipolar cells was comparable to normal light
responses, overcoming the normal slowmelanopsin kinetics. The
regained visual information also resulted in better performances
in visually guided behavioral tests. As Opto-mGluR6 was
tailored to piggyback on the mGluR6-driven G-protein cascade,
there are two reports proving that ectopical expression of
human rhodopsin, the photopigment of rod photoreceptors, in
ON bipolar cells leads to a restoration of light responses in
formerly blind rd1 retinas (Cehajic-Kapetanovic et al., 2015;
Gaub et al., 2015). Mechanistically, the recruited G-protein
cascade members are currently unknown. The treated formerly
blind retinas regained light-sensitivity with 200-fold lower
intensity than ChR2: whereas ChR2 is only active over a ∼2
log unit range of intensity, rhodopsin responses span over
a 5 log unit range of intensities. Rhodopsin-mediated VEPs
in formerly blind mice were detectable, and these mice also
succeeded in visually guided behavioral tests. The light intensity
needed for rhodopsin activation was similar to synthetic Opto-
mGluR6. The regained responses of ganglion cells covered
the full wildtype spectrum from excitatory to inhibitory,
either being sustained or transient (Cehajic-Kapetanovic et al.,
2015).
Taken together, the optogenetic toolbox for resensitizing
ON bipolar cells is well equipped. The mGluR6 promoter
element and its tandem version mediate sufficient and cell-
type-specific transgene expression. Substantial AAV capsid
modifications, followed by inner vitreal injections, have
overcome inefficient transfection of inner retinal cell types.
By this approach, about half of the retinal pathway, namely
the ON pathway, can be restored, which subsequently leads
to restored retinal signal processing and thereby, more
aspects of the visual scene are sent, encoded as trains of
action potentials, to higher brain areas. It is only a matter
of time before specific OFF bipolar cell promoter elements
are discovered, which would allow a spectrally-shifted
optogene to be targeted to OFF channels. Thereby, both
major retinal pathways would be restored, and would likely
improve the quality of optogenetic vision. Alternatively,
and if specific promoter elements become available, specific
amacrine cells, such as the AII type could be targeted.
Due to its specific connections, this would be able to drive
ON and OFF ganglion cells separately by one depolarizing
optogene. Of note, but not included here, there are also
alternative photochemical reactivation approaches in blind
retinas (Polosukhina et al., 2012; Tochitsky et al., 2014).
Whenever photoreceptors in retinal degeneration diseases
are lost, targeting inner retinal neurons with DNA-encoded
light sensors is an attractive strategy to restore retinal
processing features and overall visual function in formerly
blind patients.
TARGETING RETINAL PHOTORECEPTORS
It has been thought that both photoreceptor types, rods
and cones, die rather fast in retinal degeneration diseases,
resulting in a retina completely depleted of photoreceptors.
Therefore, the therapeutic window for targeting photoreceptors
was thought to be very short. However, it has been
shown that in RP, cones lose their light-sensitive OS
and their cell bodies, then merge with the INL over
time (Lin et al., 2009; Busskamp et al., 2010). Although
transcripts of cone-specific markers were still expressed,
the encoded proteins were not synthesized. Therefore,
immunostainings for these markers did not stain, leading
to the conclusion that cone photoreceptors had completely
degenerated. In addition, some patients with late-stage
RP had still areas with functional photoreceptors, or had
cone photoreceptor cell bodies in the fovea (Lin et al., 2009;
Jacobson et al., 2010). Therefore, the progression of complete
photoreceptor loss appears to be more variable than previously
believed, suggesting that there are patients with extended
therapeutic windows for reactivating cone photoreceptors
(Figure 8).
Photoreceptors can be easily targeted by AAV injections
into the subretinal space, leading to a reversible detachment of
the retina from the RPE (Bainbridge et al., 2008). Surrounding
photoreceptors and RPE cells incorporate the viral particles.
There are many photoreceptor-specific promoter elements
for transgene expression restriction in rods and/or cones.
Thereby, recombinant AAV genomes are not transcribed
in RPE cells. The injection of liquids into the subretinal
space is currently a standard procedure in laboratory settings
for mice, rats, dogs, pigs and nonhuman primates (Li
et al., 2008; Bruewer et al., 2013; Vandenberghe et al.,
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FIGURE 8 | Targeting persisting cone photoreceptors. To maintain the
maximum computational capacity of the retinal circuit, restoring photoreceptor
function using optogenes is a valid option for RP patients whose cones are
viable, but lack OS.
2013; Ye et al., 2016) as well as for clinical applications
such as the RPE65 treatment in LCA (Bainbridge et al.,
2008).
Resensitizing photoreceptor cells in diseases leading to
blindness resemble a reactivation of retinal pathways leading
to complete inner retinal networks, which can process the
light information. Busskamp et al. (2010) of Botond Roska’s
group applied an enhanced hyperpolarizing light-sensitive
chloride pump, called eNpHR (Gradinaru et al., 2008),
specifically to remaining cone photoreceptors in two RP mouse
models, thereby restoring the ON and OFF pathways as well
as retinal processing features such as direction selectivity.
The expression of eNpHR was restricted to photoreceptors
by using specific promoter elements. This was important,
since eNpHR expression in downstream neuronal cell types
would lead to inhibition, removing these cells from the
visual pathways. As recorded by VEPs, the light information
was sent to cortical areas, also resulting in sophisticated
visually guided behavioral changes. The eNpHR expression
was well tolerated in wildtype control mice: along with
gaining their dichromatic vision, these mice experienced
a sensitivity shift towards higher wavelengths, highlighting
that the intrinsic phototransduction cascade and the ectopic
optogene were both at work. There were no signs of
any toxic eNpHR effects detectable. Furthermore, eNpHR
was shown to hyperpolarize human photoreceptors in post-
mortem retinal explants. The peak of eNpHR activity is
at 580 nm, and photons with this wavelength cause less
photochemical damage. The amount of light for a saturated
eNpHR response was safe, according to European guidelines.
The range of eNpHR activity spanned 2.3 log units of light.
Further sensitivity improvements were achieved by applying
more sensitive hyperpolarizing optogenes (Chuong et al.,
2014). Based on the recent rhodopsin expression in inner
retinal neurons, rhodopsin might also work in remaining
cone photoreceptor cell bodies and would result in a higher
sensitivity.
It is thought that resensitizing photoreceptors would restore
a relatively high resolution. Normally, cones form stacks of cell
bodies in the fovea but each of their OS serves as a light-sensitive
antenna (Provis et al., 2013). Therefore, the sizes of the OS define
the highest visual resolution. Since the cone OS are lost in RP,
and eNpHR is expressed in the membrane of the entire cell body,
its size defines the restored visual resolution. In addition, cone
cell bodies in the same vertical stack would respond to identical
stimuli. However, these theoretical calculations might need to be
corrected when the first patients are treated and tested, and they
are able to report their experiences.
CONCLUSION
Depending on the disease state and which cell types remain,
there are multiple therapeutic interventions possible. From a
biophysical perspective, optimizing light sensitivity of microbial
opsins is at its limits. However, increasing expression levels
and cellular targeting, as well as piggy-backing on the intrinsic
G-protein cascade for signal amplification, will improve light
sensitivity. It will also be interesting to see how hyperpolarizing
anion channels perform in photoreceptors or OFF bipolar
and ganglion cells. All microbial optogenes lack the signal
amplification generated by the phototransduction cascade
and therefore, their sensitivity will not reach the levels of
intrinsic opsins. Even harnessing G-protein cascades will not
tune light sensitivity towards natural conditions because the
special light-catching compartments of photoreceptors, the
OS, are still missing. There are currently some ongoing
efforts to regenerate these cellular compartments in order
to restore intrinsic cone vision (Busskamp et al., 2014).
In addition, combinations of optogenetic interventions with
neuroprotective approaches (Sahel and Roska, 2013) might be
essential when, despite restored function the degeneration still
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progresses as reported in LCA canine models (Cideciyan et al.,
2013).
Under the current settings, the next goal is to restore
monochromatic vision using optogenes. Ultimately, restoring
color vision by spectrally shifted optogenes is theoretically
possible, but technically extremely challenging. Medical devices,
amplifying goggles (Cepko, 2010), will soon be on themarket and
enable visual perception by microbial optogenes under normal
light conditions. Starting optogenetic trials with less sensitive
optogenes could also be a safety feature. If resensitizing retinal
cells in blind patients causes side effects such as headaches upon
optical stimulation, it would be possible to simply remove the
goggles to stop optogenetic visual activity.
In summary, there has been promising progress in the vision
restoration field. The translation of optogenetic approaches
has been thoughtfully discussed by experts (Francis et al.,
2013). Of note is that the first clinical trial using wild
type ChR2 was started end of 2015 (NCT02556736). The
application of optogenes is a promising and mutation-
independent approach to restoring vision. The contributions
of the entire field are invaluable and it is very exciting
that these therapeutic interventions will be implemented very
soon.
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